Marker Therapeutics (MRKR) Other Non-Current Liabilities (2011 - 2015)
Marker Therapeutics (MRKR) posted quarterly Other Non-Current Liabilities of $26.5 million for Q4 2015, up 294266.67% year-over-year from N/an in Q4 2014, and down 17.71% quarter-over-quarter from $32.2 million in Q3 2015.
Marker Therapeutics (MRKR) Other Non-Current Liabilities (2011 - 2015) Analysis & Trends
Marker Therapeutics (MRKR) has reported Other Non-Current Liabilities for 5 consecutive years, with $26.5 million the latest figure, recorded in Q4 2015.
- In Q4 2015, Other Non-Current Liabilities rose 294266.67% year-over-year to $26.5 million; the TTM figure through Dec 2015 stood at $26.5 million (up 294266.67% YoY), while the FY2015 annual figure was $26.5 million, up 294266.67% from the prior year.
- Other Non-Current Liabilities declined to $26.5 million in Q4 2015 per MRKR's latest filing, from $32.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $70.0 million in Q2 2015 and bottomed at $9000.0 in Q4 2014.
- Historically, Other Non-Current Liabilities has averaged $15.7 million across 5 years, with a median of $1.3 million in 2011.
- Annual changes were most pronounced in 2012 — Other Non-Current Liabilities sank 48.62% — and 2015, when it soared 294266.67%.
- Marker Therapeutics' Other Non-Current Liabilities stood at $1.3 million in 2011, then tumbled by 48.62% to $677086.0 in 2012, then plunged by 31.72% to $462293.0 in 2013, then sank by 98.05% to $9000.0 in 2014, then jumped by 294266.67% to $26.5 million in 2015.
- Business Quant data shows MRKR's Other Non-Current Liabilities at $26.5 million in Q4 2015, $32.2 million in Q3 2015, and $70.0 million in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 26.49 Mn |
| Sep 30, 2015 | 32.20 Mn |
| Jun 30, 2015 | 69.96 Mn |
| Mar 31, 2015 | 9.00 Mn |
| Dec 31, 2014 | 9,000.00 |
| Mar 31, 2013 | 462,293.00 |
| Dec 31, 2012 | 677,086.00 |
| Sep 30, 2012 | 871,858.00 |
| Dec 31, 2011 | 1.32 Mn |